Dynamics of the sexual hormones level on the background of the non-hormonal correction of climacteric disorders in patients with the metabolic syndrome

2016 ◽  
Vol 10 (1) ◽  
pp. 0-0
Author(s):  
Бериханова ◽  
R. Berikhanova ◽  
Миненко ◽  
I. Minenko
Keyword(s):  
Metabolic Syndrome ◽  
Randomized Study ◽  
Follicle Stimulating Hormone ◽  
Diet Therapy ◽  
Positive Influence ◽  
Alternative Methods ◽  
Therapeutic Exercise ◽  
Sexual Hormones ◽  
Basic Group ◽  
The Metabolic Syndrome

The article presents the results of the randomized study with the participation of 120 women aged from 45 to 50 years with the metabolic syndrome. The authors determined the levels of the follicle stimulating hormone, luteinizing hormone, estradiol in the dynamics on the background of the application of different combinations of the non-hormonal methods of the correction of the disorders depending on age. On the completion of six months of therapy substantial changes in the hormonal background are revealed in the basic group of patients receiving the non-hormonal complex (diet therapy, psychotherapy, physiotherapy, the therapeutic exercise) and the orally vitamin mineral complex: a decrease in the level FSG to 35,2%, LG- to 25,2%, raising the level of estradiol by 76,3%. The obtained results demonstrate the positive influence of the association of the alternative methods of the correction of climacteric disorders in patients with MS to the hormonal profile. This suggests the pathogenetic justification of the non-drug therapy.

Abstract 2373: Diet Plus Pravastatin Treatment Reduces The Risk Of Cardiovascular Disease And Total Mortality In Patients With Metabolic Syndrome: Sub-analysis From A Large-scale Primary Prevention Trial With Pravastatin (MEGA Study)

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Teruhiko Matsushima ◽  
Susumu Koseki ◽  
Haruo Nakamura
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Risk Reduction ◽  
Ldl Cholesterol ◽  
Significant Risk ◽  
Total Mortality ◽  
Diet Therapy ◽  
Cvd Risk ◽  
The Metabolic Syndrome ◽  
Increased Risk

Background: The metabolic syndrome is related to an increased risk of cardiovascular disease (CVD), as reported by numerous studies. In this analysis, we investigated the relationship between the metabolic syndrome (MetSyn) and CVD risk in hypercholesterolemic patients and the effect of pravastatin treatment in the MEGA Study population. Methods: The MetSyn was defined according to modified National Cholesterol Education Program (NCEP) criteria, namely, the presence of three or more risk factors: 1)obesity (body mass index ≥25 kg/m 2 ), 2)hypertriglyceridemia (≥150 mg/dL), 3)low HDL cholesterol (<40 mg/dL in men and <50 mg/dL in women), 4)hypertension (SBP≥130 mmHg and/or DBP≥85 mmHg), 5)hyperglycemia (fasting glucose ≥100 mg/dL). The risk of CVD and total mortality was compared in patients with and without MetSyn. The effect of pravastatin plus diet therapy in the patients with MetSyn was compared to those without MetSyn, and moreover these comparisons were conducted in two groups, divided according to their LDL cholesterol levels (cut point: 156.9 mg/dL). Results: A total of 2,636 (33.7%) of the 7,832 hypercholesterolemic patients enrolled in MEGA had MetSyn. A 1.9 times higher incidence of CVD was found in the patients with, compared to those without, MetSyn. The risk of CVD in patients with MetSyn was very similar to that in patients with high LDL cholesterol (≥156.9 mg/dL) and with low LDL cholesterol (<156.9 mg/dL). Notably, a 36% significant risk reduction for CVD and 50% risk reduction for total mortality were observed in the patients with MetSyn treated with pravastatin plus diet treatment compared to diet therapy alone. Moreover, the greatest CVD risk reduction was observed in the high LDL-C group with MetSyn compared to those without MetSyn (Hazard ratio 0.44 vs. 0.56, respectively, interaction p=0.07). Conclusion: Metabolic syndrome increases the risk of CVD regardless of the presence or absence of hypercholesterolemia. Diet plus pravastatin treatment is effective for the prevention of CVD for patients with hypercholesterolemia and MetSyn.

Safety evaluation of the non-hormonal correction of climacteric disorders in patients with the metabolic syndrome (short report)

2015 ◽  
Vol 9 (2) ◽  
pp. 0-0
Author(s):  
Бериханова ◽  
R. Berikhanova ◽  
Миненко ◽  
R. Minenko
Keyword(s):  
Metabolic Syndrome ◽  
Safety Evaluation ◽  
Red Clover ◽  
Diet Therapy ◽  
Control Group ◽  
Comprehensive Treatment ◽  
Short Report ◽  
Cytologic Examination ◽  
The Metabolic Syndrome ◽  
Kupperman Index

The safety evaluation of the complex non-hormonal correction of climacteric disorders was carried out among 120 women with the metabolic syndrome during the period of peri- and post-menopause. Three equal groups of 40 patients were formed. In the main group a non-pharmacological complex was applied (diet therapy, psychotherapy, physical therapy, exercise therapy) and the intake of the extract of dry red clover (Trifoliumpratense), standardized to 40% of the Isoflavones in a dose of 160 mg (1 capsule) oral per day was prescribed. In the first control group only non-pharmacological methods were used. The women of the second control group took the extract of dry red clover only. The degree of severity of the climacteric syndrome was measured by the Kupperman index. Before and six months after treatment in all groups the thickness of endometrium was estimated by trans-vaginal sonogra-phy, cytologic examination of PAP-tests and breast examinations. After six months of treatment the Kupperman index has significantly declined in the first group – to 4,3±2,2, i.e. more by five times (&#60;0,05 in comparison to the index registered before treatment). Only one case of individual intolerance was registered – in the first group on the second day of the intake of the extract of the dry red clover. As a result this patient was excluded from the research. No initiations of proliferation processes in the endometrium, mammary glands and no oncogenic influence on the epithelium of uterine cervix have been registered in any of experimental groups. Thus, the optimal effective and safe treatment for climacteric disorders among women with the metabolic syndrome showed to be a comprehensive treatment approach with the use of phyto-estrogen and non-pharmacological correction incorporated.

scholarly journals Adipokines and Sexual Hormones Associated with the Components of the Metabolic Syndrome in Pharmacologically Untreated Subjects: Data from the Brisighella Heart Study

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Arrigo F. G. Cicero ◽  
Paolo Magni ◽  
Massimo Moré ◽  
Massimiliano Ruscica ◽  
Elena Dozio ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Protective Factor ◽  
Plasma Lipids ◽  
Sexual Hormones ◽  
Men And Women ◽  
The Metabolic Syndrome ◽  
Heart Study ◽  
Main Factor

We evaluated the association of the sex hormone pattern and the serum level of the main adipokines to metabolic syndrome (MS) and its components in 199 pharmacologically untreated subjects. Men and women included in the age-class subgroups were matched for body mass index, waist circumference, blood pressure, heart rate, fasting plasma glucose, and plasma lipids. Men without MS had significantly lower leptin/adiponectin ratio than men with MS. Women without MS had lower leptin and leptin/adiponectin ratio than women with MS but had significantly higher adiponectin, estrone, and dehydroepiandrosterone levels. In men, the leptin/adiponectin ratio is the main factor associated to MS diagnosis (OR: 3.36, 95% CI 1.40–8.08), while in women adiponectin alone appears to be a protective factor (OR: 0.87, 95% CI 0.79–0.95). In conclusion, in a sample of pharmacologically untreated subjects, leptin/adiponectin ratio seems to be the factor more strongly associated to MS and its components.

scholarly journals Whole Grain Rye Intake, Reflected by a Biomarker, Is Associated with Favorable Blood Lipid Outcomes in Subjects with the Metabolic Syndrome – A Randomized Study

PLoS ONE ◽  
2014 ◽  
Vol 9 (10) ◽  
pp. e110827 ◽  
Author(s):  
Ola Kally Magnusdottir ◽  
Rikard Landberg ◽  
Ingibjorg Gunnarsdottir ◽  
Lieselotte Cloetens ◽  
Björn Åkesson ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Randomized Study ◽  
Blood Lipid ◽  
Whole Grain ◽  
The Metabolic Syndrome

scholarly journals Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study

2014 ◽  
Vol 112 (3) ◽  
pp. 438-445 ◽  
Author(s):  
Tannaz Eslamparast ◽  
Farhad Zamani ◽  
Azita Hekmatdoost ◽  
Maryam Sharafkhah ◽  
Sareh Eghtesad ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Pilot Study ◽  
Diet Therapy ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Balanced Diet ◽  
The Metabolic Syndrome ◽  
Synbiotic Supplementation ◽  
Mean Differences

To evaluate the effects of synbiotic supplementation on insulin resistance and lipid profile in individuals with the metabolic syndrome, we conducted a randomised, double-blind, placebo-controlled pilot study on thirty-eight subjects with the metabolic syndrome; they were supplemented with either synbiotic capsules containing 200 million of seven strains of friendly bacteria plus fructo-oligosaccharide or placebo capsules twice a day for 28 weeks. Both the synbiotic (G1) and the placebo (G2) groups were advised to follow an energy-balanced diet and physical activity recommendations. Parameters related to the metabolic syndrome and insulin resistance were measured every 7 weeks during the course of the study. After 28 weeks of treatment, the levels of fasting blood sugar and insulin resistance improved significantly in the G1 group (P< 0·001). Both the G1 and G2 groups exhibited significant reductions in TAG levels ( − 71·22 v. − 10·47 mg/dl ( − 0·80 v. − 0·12 mmol/l) respectively; P< 0·001) and total cholesterol levels ( − 21·93 v. − 14·2 mg/dl ( − 0·57 v. − 0·37 mmol/l) respectively; P= 0·01), as well as increases in HDL levels (+7·7 v. +0·05 mg/dl (+0·20 v. +>0·01 mmol/l) respectively; P< 0·001). The mean differences observed were greater in the G1 group. No significant changes were observed in LDL levels, waist circumference, BMI, metabolic equivalent of task and energy intake between the groups. The present results indicate that synbiotic supplementation increases the efficacy of diet therapy in the management of the metabolic syndrome and insulin resistance.

scholarly journals Melatonin in menopausal metabolic syndrome formation.

2018 ◽  
Vol 96 (2) ◽  
pp. 116-122
Author(s):  
E. V. Bruhina ◽  
A. G. Mamontova ◽  
Elena N. Usoltseva
Keyword(s):  
Metabolic Syndrome ◽  
Animal Studies ◽  
Reproductive Function ◽  
High Energy ◽  
Positive Influence ◽  
Formation Mechanisms ◽  
Free Access ◽  
Hormonal Changes ◽  
Diabetes Mellitus Type Ii ◽  
The Metabolic Syndrome

Women’s life has changed considerably during the last decades. Often it can be characterized by hypodynamia, high-energy, refined diet, disturbance of circadian rhythms (working in shifts, staying for a long time in front of the TV screen or computer). All these factors, as well as, hormonal changes, which are connected with reduction of women’s reproductive function, increase the risk of metabolic syndrome. Thus, search of new therapeutic agent is currently taking place. Such medicament should effect on all symptoms of metabolic syndrome, and at the same time should be well co-administered with other drugs. Probably, one of such drugs is melatonin. The literature search was held in Russian (elibrary, cyberleninka.ru) and international (pubmed, wiley online library) data bases for the last seven years. Free access to the full document was of top-priority. The choice was limited by two languages: Russian and English. The article contains information about the metabolic syndrome frequency in a population, and metabolic changes in women’s organism in post-menopause. The article focuses on the role of melatonin in the menopause metabolic syndrome formation. Mechanisms of the melatonin influence on all the metabolic syndrome components: obesity, arterial hypertension, blood lipids changes, and insulin resistance are studied. The correlation between the melatonin secretion decrease and the atherosclerosis and diabetes mellitus type II formation is observed. The article contains data about animal experiences and the melatonin use for its management in biological models. It is proved that melatonin has positive influence on metabolic syndrome symptoms in animal studies.

Sign in / Sign up

Export Citation Format

Share Document